|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNFX1 |
Gene summary for ZNFX1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNFX1 | Gene ID | 57169 |
| Gene name | zinc finger NFX1-type containing 1 | |
| Gene Alias | ZNFX1 | |
| Cytomap | 20q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0006325 | UniProtAcc | Q9P2E3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57169 | ZNFX1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.60e-04 | 3.91e-01 | -0.1808 |
| 57169 | ZNFX1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.12e-02 | 3.54e-01 | -0.0811 |
| 57169 | ZNFX1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.01e-02 | 1.95e-01 | -0.1088 |
| 57169 | ZNFX1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.03e-03 | 2.67e-01 | -0.1954 |
| 57169 | ZNFX1 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.91e-07 | 9.27e-01 | -0.2602 |
| 57169 | ZNFX1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.97e-10 | 5.21e-01 | -0.059 |
| 57169 | ZNFX1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.54e-22 | 7.60e-01 | 0.3859 |
| 57169 | ZNFX1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.61e-09 | 6.81e-01 | 0.2585 |
| 57169 | ZNFX1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.43e-04 | 2.86e-01 | 0.3005 |
| 57169 | ZNFX1 | LZE4T | Human | Esophagus | ESCC | 1.39e-08 | 3.49e-01 | 0.0811 |
| 57169 | ZNFX1 | LZE5T | Human | Esophagus | ESCC | 2.51e-07 | 3.24e-01 | 0.0514 |
| 57169 | ZNFX1 | LZE8T | Human | Esophagus | ESCC | 2.32e-07 | 2.05e-01 | 0.067 |
| 57169 | ZNFX1 | LZE20T | Human | Esophagus | ESCC | 1.78e-11 | 3.27e-01 | 0.0662 |
| 57169 | ZNFX1 | LZE22T | Human | Esophagus | ESCC | 2.16e-03 | 3.99e-01 | 0.068 |
| 57169 | ZNFX1 | LZE24T | Human | Esophagus | ESCC | 2.75e-16 | 5.78e-01 | 0.0596 |
| 57169 | ZNFX1 | LZE21T | Human | Esophagus | ESCC | 1.21e-06 | 2.96e-01 | 0.0655 |
| 57169 | ZNFX1 | LZE6T | Human | Esophagus | ESCC | 6.06e-03 | 1.44e-01 | 0.0845 |
| 57169 | ZNFX1 | P1T-E | Human | Esophagus | ESCC | 2.03e-07 | 4.34e-01 | 0.0875 |
| 57169 | ZNFX1 | P2T-E | Human | Esophagus | ESCC | 2.52e-18 | 4.43e-01 | 0.1177 |
| 57169 | ZNFX1 | P4T-E | Human | Esophagus | ESCC | 7.29e-06 | 1.63e-01 | 0.1323 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
| GO:00063251 | Colorectum | SER | chromatin organization | 89/2897 | 409/18723 | 4.15e-04 | 6.17e-03 | 89 |
| GO:00063252 | Colorectum | MSS | chromatin organization | 107/3467 | 409/18723 | 7.22e-05 | 1.21e-03 | 107 |
| GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
| GO:00400295 | Esophagus | ESCC | regulation of gene expression, epigenetic | 74/8552 | 105/18723 | 2.24e-07 | 3.42e-06 | 74 |
| GO:00708281 | Esophagus | ESCC | heterochromatin organization | 31/8552 | 46/18723 | 2.42e-03 | 1.06e-02 | 31 |
| GO:0045814 | Esophagus | ESCC | negative regulation of gene expression, epigenetic | 32/8552 | 50/18723 | 6.90e-03 | 2.52e-02 | 32 |
| GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
| GO:0040029 | Liver | HCC | regulation of gene expression, epigenetic | 61/7958 | 105/18723 | 9.02e-04 | 5.31e-03 | 61 |
| GO:00400294 | Oral cavity | OSCC | regulation of gene expression, epigenetic | 59/7305 | 105/18723 | 2.62e-04 | 1.68e-03 | 59 |
| GO:000632510 | Oral cavity | OSCC | chromatin organization | 190/7305 | 409/18723 | 1.17e-03 | 5.97e-03 | 190 |
| GO:004002911 | Oral cavity | LP | regulation of gene expression, epigenetic | 39/4623 | 105/18723 | 3.00e-03 | 2.05e-02 | 39 |
| GO:000632515 | Oral cavity | EOLP | chromatin organization | 84/2218 | 409/18723 | 2.68e-07 | 8.16e-06 | 84 |
| GO:00400292 | Oral cavity | EOLP | regulation of gene expression, epigenetic | 24/2218 | 105/18723 | 1.07e-03 | 7.87e-03 | 24 |
| GO:000632521 | Oral cavity | NEOLP | chromatin organization | 70/2005 | 409/18723 | 4.97e-05 | 6.83e-04 | 70 |
| GO:00400293 | Oral cavity | NEOLP | regulation of gene expression, epigenetic | 24/2005 | 105/18723 | 2.48e-04 | 2.55e-03 | 24 |
| GO:0070828 | Oral cavity | NEOLP | heterochromatin organization | 11/2005 | 46/18723 | 7.99e-03 | 3.95e-02 | 11 |
| GO:000632520 | Thyroid | PTC | chromatin organization | 183/5968 | 409/18723 | 2.55e-08 | 5.70e-07 | 183 |
| GO:00400297 | Thyroid | PTC | regulation of gene expression, epigenetic | 57/5968 | 105/18723 | 1.60e-06 | 2.25e-05 | 57 |
| GO:0031507 | Thyroid | PTC | heterochromatin assembly | 22/5968 | 39/18723 | 1.32e-03 | 7.47e-03 | 22 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNFX1 | SNV | Missense_Mutation | c.2131N>A | p.Leu711Ile | p.L711I | Q9P2E3 | protein_coding | tolerated(0.14) | possibly_damaging(0.796) | TCGA-A2-A0YI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Femara | SD | |
| ZNFX1 | SNV | Missense_Mutation | c.418N>A | p.Gln140Lys | p.Q140K | Q9P2E3 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| ZNFX1 | SNV | Missense_Mutation | novel | c.2372N>C | p.Gly791Ala | p.G791A | Q9P2E3 | protein_coding | tolerated(0.59) | benign(0.01) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| ZNFX1 | SNV | Missense_Mutation | c.3017N>G | p.Glu1006Gly | p.E1006G | Q9P2E3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNFX1 | SNV | Missense_Mutation | c.4343N>T | p.Ser1448Phe | p.S1448F | Q9P2E3 | protein_coding | deleterious(0) | possibly_damaging(0.448) | TCGA-C8-A138-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ZNFX1 | SNV | Missense_Mutation | c.617A>C | p.His206Pro | p.H206P | Q9P2E3 | protein_coding | deleterious(0.01) | possibly_damaging(0.601) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| ZNFX1 | insertion | Frame_Shift_Ins | novel | c.3357_3358insGTGTGGGCACAGTCAACCGGTAAAAT | p.Gln1120ValfsTer28 | p.Q1120Vfs*28 | Q9P2E3 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZNFX1 | insertion | Frame_Shift_Ins | novel | c.4995_4996insAC | p.Ala1666ThrfsTer19 | p.A1666Tfs*19 | Q9P2E3 | protein_coding | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
| ZNFX1 | insertion | Nonsense_Mutation | novel | c.4994_4995insCAAATCTCACCCCTTCTCTCCTGCAAATTAGTGGACA | p.Lys1665AsnfsTer11 | p.K1665Nfs*11 | Q9P2E3 | protein_coding | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
| ZNFX1 | insertion | Frame_Shift_Ins | novel | c.4203_4204insTGTAGTCCCTGCGTGGAAC | p.Val1402CysfsTer64 | p.V1402Cfs*64 | Q9P2E3 | protein_coding | TCGA-A8-A0AB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |